Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Nabi (NABI) -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (270)	8/29/2000 7:07:16 AM
From: Oak Tree	Respond to of 354

Regarding market size for StaphVax. I can only guess - either large of small. Large case: In general the board of pediatrics has been an open door for new vaccines. This is in part because the use of vaccines for several diseases (polio, cholera, smallpox, mumps measles...) has been such a medical miracle. More recently however pediatricians are being critisized for being vaccine happy. So they will want to be sure before they add a new vaccine. Staph is a major cause of childhood morbidity and mortality, and thus could be a realistic vaccine for all children. SMALL CASE: Adults also have some bad infections, usually however when they are immune suppressed for one reason or another. For example a staph pneumonia in a trauma victim, AIDS patient, or in the elderly. Staph is very virulent, and the vaccine is unlikely to be perfect like for example the polio vaccine is. The imperfection may limit its general acceptance. Hence, it may end up more like the pneumovax vaccine. In that case the market is small.